Featured Courses

Final Chapter: Post-COVID-19 Fibrosis and the Role of Antifibrotic Therapy Management

AMA PRA Category 1 Credit(s)^TM

Double Jeopardy: COVID-19 the Evil Character for ILD Patients

AMA PRA Category 1 Credit(s)^TM

Connecting Care: Expert Answers About COVID-19 Treatment With Neutralizing Monoclonal Antibodies

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), AANP Contact Hour(s), CE for Pharmacists

Addressing the Real-World Challenge of HCV Cure in People Who Inject Drugs: Opportunities for Current and New HCV Treaters

AMA PRA Category 1 Credit(s)^TM

HIV Prevention in Primary Care Practice: A PrEP Primer (An HIV Prevention eHealth Source™)

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s)

At-Risk Patients Hidden in Plain Sight: Real-World Strategies for Screening and Treating Hepatitis B Virus

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists, ABIM MOC Credit, CNE Contact Hour(s)

Streamlining the Journey to a Cure: Optimizing the Hepatitis C Virus Care Cascade

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s), CE for Pharmacists

Straight Talk with the Expert Surrounding COVID-19 and Your Patients with ILD

AMA PRA Category 1 Credit(s)^TM

Starting PrEP in a 19-Year-Old African American Man With an STI

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s), AAPA Category I CME credit

New HIV Test Panels: Incorporating Strategies to Guide the Use of Antiretroviral Therapy for Prevention in High-Risk Individuals

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s), AAPA Category I CME credit

Assessing and Addressing Barriers to ART Adherence

AMA PRA Category 1 Credit(s)^TM

Two-Drug ART Regimens: Is It Time for a Paradigm Shift?

AMA PRA Category 1 Credit(s)^TM